Impacts of hyperthermic chemotherapeutic agent on cytotoxicity, chemoresistance-related proteins and PD-L1 expression in human gastric cancer cells

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi: 10.1002/ijc.29210.
   PubMed Web of Science ®Google Scholar
• Wong MCS, Huang JJ, Chan PSF, et al. Global incidence and mortality of gastric cancer, 1980–2018. JAMA Netw Open. 2021;4(7):e2118457. doi: 10.1001/jamanetworkopen.2021.18457.
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Bandou E, Kawamura T, et al. Quantitative prognostic indicators of peritoneal dissemination of gastric cancer. Eur J Surg Oncol. 2006;32(6):602–606. doi: 10.1016/j.ejso.2006.03.003.
   PubMed Web of Science ®Google Scholar
• Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies – results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88(2):358–363. doi: 10.1002/(Sici)1097-0142(20000115)88:2<358::Aid-Cncr16>3.0.Co;2-O.
   PubMed Web of Science ®Google Scholar
• Kitayama J, Ishigami H, Yamaguchi H, et al. Treatment of patients with peritoneal metastases from gastric cancer. Ann Gastroenterol Surg. 2018;2(2):116–123. doi: 10.1002/ags3.12060.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Yonemura Y. Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology. 2000;58(2):96–107. doi: 10.1159/000012086.
   PubMed Web of Science ®Google Scholar
• Bonnot P-E, Piessen G, Kepenekian V, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. Adv Skin Wound Care. 2019;37(23):2028–2040. doi: 10.1200/JCO.18.01688.
   Google Scholar
• Dellinger TH, Han ES. State of the science: the role of HIPEC in the treatment of ovarian cancer. Gynecol Oncol. 2021;160(2):364–368. doi: 10.1016/j.ygyno.2020.12.029.
   PubMed Web of Science ®Google Scholar
• Cesna V, Sukovas A, Jasukaitiene A, et al. Narrow line between benefit and harm: additivity of hyperthermia to cisplatin cytotoxicity in different gastrointestinal cancer cells. World J Gastroenterol. 2018;24(10):1072–1083. doi: 10.3748/wjg.v24.i10.1072.
   PubMed Web of Science ®Google Scholar
• Su BC, Mo FE. CCN1 enables fas ligand-induced apoptosis in cardiomyoblast H9c2 cells by disrupting caspase inhibitor XIAP. Cell Signal. 2014;26(6):1326–1334. doi: 10.1016/j.cellsig.2014.02.019.
   PubMed Web of Science ®Google Scholar
• Tu YC, Yeh WC, Yu HH, et al. Hedgehog suppresses paclitaxel sensitivity by regulating Akt-mediated phosphorylation of bax in EGFR wild-type non-small cell lung cancer cells. Front Pharmacol. 2022;13:815308. doi: 10.3389/fphar.2022.815308.
   PubMed Web of Science ®Google Scholar
• Franken NAP, Rodermond HM, Stap J, et al. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1(5):2315–2319. doi: 10.1038/nprot.2006.339.
   PubMed Web of Science ®Google Scholar
• Qiu C, Li YQ, Liang X, et al. A study of peritoneal metastatic xenograft model of colorectal cancer in the treatment of hyperthermic intraperitoneal chemotherapy with raltitrexed. Biomed Pharmacother. 2017;92:149–156. doi: 10.1016/j.biopha.2017.04.053.
   PubMed Web of Science ®Google Scholar
• Rosa F, Galiandro F, Ricci R, et al. Survival advantage of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer: experience from a Western tertiary referral center. Langenbecks Arch Surg. 2021;406(6):1847–1857. doi: 10.1007/s00423-021-02102-2.
   PubMed Web of Science ®Google Scholar
• Wu YZ, Zheng XH, Sun CY, et al. Hyperthermic intraperitoneal chemotherapy for patients with gastric cancer based on laboratory tests is safe: a single Chinese center analysis. BMC Surg. 2022;22(1):342. doi: 10.1186/s12893-022-01795-6.
   PubMed Web of Science ®Google Scholar
• Fugazzola P, Coccolini F, Montori G, et al. Overall and disease-free survival in patients treated with CRS. J Gastrointest Oncol. 2017;8(3):572–582. doi: 10.21037/jgo.2017.03.11.
   PubMed Web of Science ®Google Scholar
• Noordhuis P, Holwerda U, Van der Wilt CL, et al. 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann Oncol. 2004;15(7):1025–1032. doi: 10.1093/annonc/mdh264.
   PubMed Web of Science ®Google Scholar
• Sara JD, Kaur J, Khodadadi R, et al. 5-Fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018;10:1758835918780140. doi: 10.1177/1758835918780140.
   Web of Science ®Google Scholar
• Wang Y, Wang WL, Dong HM, et al. Risk factors for fluoropyrimidine-induced cardiotoxicity in colorectal cancer: a retrospective cohort study and establishment of a prediction nomogram for 5-FU induced cardiotoxicity. Front Oncol. 2023;13:1017237. doi: 10.3389/fonc.2023.1017237.
   PubMed Web of Science ®Google Scholar
• Abou El Fadl MH, Bagai RK, Spiro TP, et al. 5-Fluorouracil-induced cardiotoxicity during chemotherapy for adenocarcinoma of the small bowel. Gastrointest Cancer Res. 2009;3(4):167–170.
   PubMedGoogle Scholar
• Garg MB, Lincz LF, Adler K, et al. Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: a multivariate analysis. Br J Cancer. 2012;107(9):1525–1533. doi: 10.1038/bjc.2012.421.
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Elnemr A, Endou Y, et al. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol. 2010;2(2):85–97. doi: 10.4251/wjgo.v2.i2.85.
   PubMed Web of Science ®Google Scholar
• Li Z, Deng J, Sun J, et al. Hyperthermia targeting the tumor microenvironment facilitates immune checkpoint inhibitors. Front Immunol. 2020;11:595207. doi: 10.3389/fimmu.2020.595207.
   PubMed Web of Science ®Google Scholar
• Groves TR, Farris R, Anderson JE, et al. 5-Fluorouracil chemotherapy upregulates cytokines and alters hippocampal dendritic complexity in aged mice. Behav Brain Res. 2017;316:215–224. doi: 10.1016/j.bbr.2016.08.039.
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Bruchard M, Apetoh L. Immune effects of 5-fluorouracil ambivalence matters. Oncoimmunology. 2013;2(3):e23139. doi: 10.4161/onci.23139.
   PubMed Web of Science ®Google Scholar
• Almhanna K, Strosberg J, Malafa M. Targeting AKT protein kinase in gastric cancer. Anticancer Res. 2011;31(12):4387–4392.
   PubMed Web of Science ®Google Scholar
• Ashrafizadeh M, Zarrabi A, Orouei S, et al. STAT3 pathway in gastric cancer: signaling, therapeutic targeting and future prospects. Biology. 2020;9(6):1–36. doi: 10.3390/biology9060126.
   Google Scholar
• Kang BW, Chau I. Molecular target: pan-AKT in gastric cancer. ESMO Open. 2020;5(5):e000728. doi: 10.1136/esmoopen-2020-000728.
   PubMed Web of Science ®Google Scholar
• Wei JH, Wang RQ, Lu YR, et al. Flotillin-1 promotes progression and dampens chemosensitivity to cisplatin in gastric cancer via ERK and AKT signaling pathways. Eur J Pharmacol. 2022;916:174631. doi: 10.1016/j.ejphar.2021.174631.
   PubMed Web of Science ®Google Scholar
• de Oliveira J, Felipe AV, Neto RA, et al. Association between ABCB1 immunohistochemical expression and overall survival in gastric cancer patients. Asian Pac J Cancer Prev. 2014;15(16):6935–6938. doi: 10.7314/Apjcp.2014.15.16.6935.
   PubMedGoogle Scholar
• Wang S, Guo JE, Mo ZZ, et al. Clinical significance and correlation of miR-200c and P-gp expression in gastric cancer and the effects on multidrug resistance. J Gastrointest Oncol. 2022;13(2):581–592. doi: 10.21037/jgo-22-167.
   PubMed Web of Science ®Google Scholar
• Kamoshida S, Suzuki M, Shimomura R, et al. Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer. Br J Cancer. 2007;96(2):277–283. doi: 10.1038/sj.bjc.6603546.
   PubMed Web of Science ®Google Scholar
• Peters GJ, Backus HHJ, Freemantle S, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta. 2002;1587(2–3):194–205. doi: 10.1016/S0925-4439(02)00082-0.
   PubMed Web of Science ®Google Scholar
• Chun KS, Joo SH. Modulation of reactive oxygen species to overcome 5-fluorouracil resistance. Biomol Ther. 2022;30(6):479–489. doi: 10.4062/biomolther.2022.017.
   PubMed Web of Science ®Google Scholar
• Fu Y, Yang G, Zhu F, et al. Antioxidants decrease the apoptotic effect of 5-Fu in Colon cancer by regulating src-dependent caspase-7 phosphorylation. Cell Death Dis. 2014;5(1):e983–e983. doi: 10.1038/cddis.2013.509.
   PubMedGoogle Scholar
• Liu YD, Yu L, Ying L, et al. Toll-like receptor 2 regulates metabolic reprogramming in gastric cancer via superoxide dismutase 2. Int J Cancer. 2019;144(12):3056–3069. doi: 10.1002/ijc.32060.
   PubMed Web of Science ®Google Scholar
• Han YY, Liu DD, Li LH. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727–742.
   PubMed Web of Science ®Google Scholar
• Ruiz Hispán E, Pedregal M, Cristobal I, et al. Immunotherapy for peritoneal metastases from gastric cancer: rationale, current practice and ongoing trials. J Clin Med. 2021;10(20):1–9. doi: 10.3390/jcm10204649.
   Web of Science ®Google Scholar
• Sun LL, Li CW, Chung EM, et al. Targeting glycosylated PD-1 induces potent antitumor immunity. Cancer Res. 2020;80(11):2298–2310. doi: 10.1158/0008-5472.Can-19-3133.
   PubMed Web of Science ®Google Scholar
• Zhao X, Bao YL, Meng B, et al. From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades. Front Immunol. 2022;13:920021. doi: 10.3389/fimmu.2022.920021.
   PubMed Web of Science ®Google Scholar
• Chen Y, Jia KR, Sun Y, et al. Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment. Nat Commun. 2022;13(1):4851. doi: 10.1038/s41467-022-32570-z.
   PubMed Web of Science ®Google Scholar
• Ahn S, Lee JC, Shin DW, et al. High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer (vol 23, pg 12348, 2020). Sci Rep. 2020;10(1):21552. doi: 10.1038/s41598-020-78512-x.
   PubMedGoogle Scholar